NCT00193206 - Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

May 31, 2009

Conditions

Breast Cancer

Interventions

DRUG

Gemcitabine

Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles

DRUG

Epirubicin

Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles

DRUG

Albumin-bound Paclitaxel

ABI-007 175 mg/m2 D1 q 14 days x 6 cycles

Trial Locations (13)

23601

Peninsula Cancer Institute, Newport News

29303

Spartanburg Regional Medical Center, Spartanburg

30501

Northeast Georgia Medical Center, Gainesville

32256

Integrated Community Oncology Network, Jacksonville

32804

Florida Hospital Cancer Institute, Orlando

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

37404

Chattanooga Oncology and Hematology Associates, Chattanooga

40207

Consultants in Blood Disorders and Cancer, Louisville

45242

Oncology Hematology Care, Cincinnati

71301

Hematology Oncology Life Center, Alexandria

04101

Mercy Hospital, Portland